logo
episode-header-image
Jun 2022
30m 10s

S2 003: Barbara Domayne-Hayman ➡️ From b...

Fiona Pathiraja
About this episode

From a PhD in chemistry to big pharma and biotech to startups and now investing, Barbara successfully navigates a portfolio career.

Today, she sits on the investment committees of the Cambridge Enterprise seed fund and Life Arc’s seed fund. She is also the entrepreneur in Residence at the Francis Crick Institute in London. She also runs the KQ Labs accelerator, helping data-driven scientist and health founders commercialise their ideas. Two of our portfolio companies, Mendelian and Charco Neurotech, have been through the KQ Labs programme.

An alumna of the London Business School Sloan programme, Barbara has fearlessly navigated multiple career transitions, from big pharma to biotech to startups and investing. Today, she is also an angel investor and a member of the Cambridge Angels angel investor network.

Up next
Aug 2022
S2 012: Rachael Grimaldi. Bringing healthcare communication into the 21st Century. 🏥🗣👩🏼‍⚕️
Dr Rachael Grimaldi is an anaesthetist in the NHS who founded Card Medic at the beginning of the pandemic. Rachael noticed that the PPE (Personal Protective Equipment) used to shield all health workers during covid brought massive communication barriers with it. With doctors and ... Show More
30m 2s
Jul 2022
S2 011: Matthew Beatty. Building a digital surgical clinic & health coaching for surgical patients pre- and post-op. 📲🏥🫁
Originally a doctor, Matthew Beatty was always drawn to the world of entrepreneurship, founding his first company in property technology (proptech). He then became an operator in the healthtech world by joining Huma, then called Medopad. Matt was the clinical lead of Huma’s comme ... Show More
24m 16s
Jul 2022
S2 010: Lucy Jung. Building global healthtech for Parkinson’s patients. 🇬🇧📳🇰🇷
From academia at Imperial College and the Royal College of Art, to bringing back smiles for patients with Parkinson’s disease, Lucy Jung is the founder of Charco Neurotech. Parkinsons’ Disease is the fastest growing neurodenerative disease in the world. Although the idea that vib ... Show More
26m 31s
Recommended Episodes
Sep 2024
Kate Cronin (Moderna) | Pioneering Biotech Company and their Software of Life
Fall means it's time for your annual flu and Covid shots! So, this week on The CMO Podcast, Jim welcomes Kate Cronin, the Chief Brand Officer for Moderna, the 14-year-old pioneering biotech company. Moderna achieved nearly instant awareness and fame in 2020, when it received the ... Show More
54m 15s
Jul 2
Startup Valuations, Biotech’s Crunch & AI’s Massive TAM | E2147
Today’s show:It’s another blockbuster panel of insiders, as Alex sits down with Astasia Myers from Felicis, Matt Turck from First Mark Capital, and D.A. Wallach of Time BioVentures. AI is reshaping early-stage investing, with startups raising record-setting rounds adn chasing $10 ... Show More
1h 16m
Feb 2025
Eli Lilly CEO: The Weight-Loss Drug Revolution, AI in Pharma, and Innovation
Nicolai Tangen meets with David Ricks, CEO of Eli Lilly, for a discussion about the pharmaceutical giant's remarkable journey. At the forefront is Eli Lilly's breakthrough work with weight reduction drugs, which are showing promise far beyond their original purpose - from treatin ... Show More
55m 40s
May 2024
E313 | Super Angel | Angel investing insights with Leng Lee, co-Founder and Chief Product Officer of Oui Therapeutics
Join us as Tom Wilson from Seedcamp and Anthony Danon from Cocoa talk to Leng Lee, angel investor, co-founder & Chief Product Officer at Oui Therapeutics. Leng was previously the first employee at Codecademy where he was the Head of Product, before joining MongoDB as the Director ... Show More
38m 15s
Feb 2024
48. Healthcare Private Equity Investing
Send us a textToday as a followup to last week's episode where we sat down with two doctors, we are chatting with two investors in the Healthcare Private Equity space, not only talking about that segment of the investment community but also answering the mountain of question ... Show More
49m 50s
Jan 2025
Mike Maples on 100-Baggers, David Swensen & the AI Revolution | #568
Today’s guest is Mike Maples Jr. a partner at Floodgate, a pre-seed and seed-stage venture capital firm that’s invested in companies like Twitter, Lyft, Twitch, Okta. He’s also the author of Pattern Breakers: Why Some Start-Ups Change the Future. In today’s episode, Mike shares h ... Show More
1h 11m
May 27
Katie Koch - Be A Force Multiplier - [Joys of Compounding, REPLAY]
Our teacher today is Katie Koch. Katie is the President and CEO of the TCW Group, a storied firm with over 200 billion in assets under management and a fascinating 50-year legacy as a pioneer in the investment industry. Katie just took the TCW reins in 2023 after more than 20 yea ... Show More
1h 18m
Nov 2024
Roche CEO: Future of cancer treatment, AI in Medicine and Trial Challenges
What’s next for cancer treatment and personalized medicine? How is AI reshaping the future of drug discovery? And can Europe keep pace with China’s rapid rise in health care innovation? In this episode, Nicolai welcomes Thomas Schinecker, CEO of Roche, one of the world’s largest ... Show More
53m 58s
Feb 2020
Pop Delusions: Dylan Grice on the golden age of duration, why economists are cargo cultists, and the anatomy of a forecast with Tobias Carlisle on The Acquirers Podcast
Dylan Grice is the founder of Calderwood Capital Research. Before Calderwood, Dylan was the Head of Liquid investments at Calibrium AG, a private investment office based in Zurich, Switzerland.    Prior to joining Calibrium AG in 2014, Dylan was a part of the consistently top-ran ... Show More
55m 23s